Advertisement

Bone Tumors pp 195-218 | Cite as

Bone Metastases

  • Jim S. Wu
  • Mary G. Hochman

Abstract

Metastases represent the most common bone tumor and outnumber primary bone tumors 20-to-1. Moreover, bone metastases have an extremely varied imaging appearance and are difficult to exclude from many differentials. This is especially true in patients over 40 years of age and in those with a known primary malignancy. Metastatic lesions develop when cells from the primary tumor separate and travel to distant sites, where they adhere and grow. Most often, malignant cells spread hematogenously, but they can also spread via the lymphatic system or by direct extension. The cells must be able to (1) survive the transit from the primary site and (2) once at the secondary site, develop their own blood supply, in order to grow. Thus, the vast majority of bone metastases occur in the spine and pelvis, where there is richly vascularized red marrow. Conversely, metastases are rarely found in the bones of the hands and feet, as these areas are filled with fatty marrow. Besides a rich blood supply, several growth factors are produced or stimulated by the tumor in order to optimize its establishment, survival, and growth at the secondary site.

Keywords

Apparent Diffusion Coefficient Bone Metastasis Standardize Uptake Value Bone Scintigraphy Primary Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

We thank Drs. Mark Schweitzer and Phillip Kuo for helpful discussions related to this chapter.

Suggested Reading

  1. 1.
    Fidler M. Incidence of fracture through metastases in long bones. Acta Orthop Scand. 1981;52:623–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3:53–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Graham TS. The ivory vertebra sign. Radiology. 2005;235:614–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Greenspan A, Jundt G, Remagen W. Differential diagnosis in orthopaedic oncology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.Google Scholar
  6. 6.
    Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97:834–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;249:256–264.Google Scholar
  8. 8.
    Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80:1546–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Rodan GA. The development and function of the skeleton and bone metastases. Cancer. 2003;97:726–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Resnick D, editor. Diagnosis of bone and joint disorders. 4th ed. Philadelphia, PA: W.B. Saunders; 2002.Google Scholar
  11. 11.
    Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80:1595–607.PubMedCrossRefGoogle Scholar
  12. 12.
    Taira AV, Herfkens RJ, Gambhir SS, Quon A. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007;243:204–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:325–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jim S. Wu
    • 1
  • Mary G. Hochman
    • 1
  1. 1.Department of Radiology Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations